Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY8 | P40145 | 9/20 | 0.53 |
| ▸ | ADCY1 | Q08828 | 9/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249308 | 0.88 | SLC2A1 (0.52) | ADCY8ADCY1SLC2A1HTR2BSPR | |
| SCHEMBL23249624 | 0.85 | SLC2A1 (0.45) | ADCY8ADCY1SLC2A1HTR2BSPR | |
| SCHEMBL23249750 | 0.85 | ADCY1 (0.73) | ADCY8ADCY1SLC2A1HTR2B | |
| SCHEMBL23249441 | 0.85 | SLC2A1 (0.49) | ADCY8ADCY1SLC2A1SPRDCTPP1 | |
| SCHEMBL23249468 | 0.85 | SPR (0.48) | SLC2A1SPRSMN1; SMN2 | |
| SCHEMBL23249463 | 0.84 | SLC2A1 (0.48) | ADCY8ADCY1SLC2A1SPRDCTPP1 | |
| SCHEMBL23249654 | 0.84 | SLC2A1 (0.47) | ADCY8ADCY1SLC2A1DCTPP1TNKS2 | |
| SCHEMBL23259342 | 0.84 | SLC2A1 (0.47) | ADCY8ADCY1SLC2A1SPRDCTPP1 | |
| SCHEMBL23249431 | 0.83 | SLC2A1 (0.47) | ADCY8ADCY1SLC2A1SPRDCTPP1 | |
| SCHEMBL23249650 | 0.83 | ADCY1 (0.49) | ADCY8ADCY1SLC2A1SPRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-02 | — | — | US | disclosed |
| WO-2021077102-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021077102-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | TUBB, TUBB1, TUBA1C | ADCY8 4219/4885ADCY1 4578/4885SLC2A1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.